FDAnews
www.fdanews.com/articles/88297-neose-technologies-inc-shares-fall-after-study-start-delayed-by-further-fda-questions

NEOSE TECHNOLOGIES, INC. SHARES FALL AFTER STUDY START DELAYED BY FURTHER FDA QUESTIONS

July 12, 2006

Neose Technologies, Inc. today provided an update on its clinical development program for NE-180, the Company's long-acting, GlycoPEGylated erythropoietin for the treatment of anemia. The company has concluded the dosing and safety follow-up for its Phase I trial in Western Europe. Final analyses of pharmacokinetic data and other parameters are ongoing. NE-180 was generally well-tolerated at the doses tested, and the expected increases in reticulocytes and hemoglobin were observed in both the intravenous and subcutaneous dose groups.

BioSpace (http://www.biospace.com/news_story.aspx?StoryID=23922&full=1)